Mutations in critical domains confer the human mTOR gene strong tumorigenicity

Journal of Biological Chemistry

Volumn 288, Issue 9, 2013, Pages 6511-6521

  Murugan, Avaniyapuram Kannan ^a   Alzahrani, Ali ^a   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHYMIC; CELL TRANSFORMATION; CRITICAL DOMAIN; GAIN-OF FUNCTION; HUMAN CANCER; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); NIH-3T3 CELLS; NUDE MICE; ONCOGENIC POTENTIAL; PHOSPHATIDYLINOSITOL; PROTEIN KINASE; PROTEIN KINASE ACTIVITIES; STABLE EXPRESSION; THERAPEUTIC TARGETS; TRANSFECTED CELLS; TRANSIENT EXPRESSION; TUMOR FORMATION; TUMORIGENESIS; TUMORIGENICITY;

AMINO ACIDS; CELL SIGNALING; DISEASES; ENZYMES; GENE EXPRESSION; PROTEINS; TISSUE CULTURE;

ANTIBIOTICS;

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE B; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL STRAIN 3T3; CELL STRAIN HEK293; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; MAMMALIAN TARGET OF RAPAMYCIN GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSIENT EXPRESSION; TUMOR GROWTH;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874786484     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.399485     Document Type: Article

References (45)

1. Wullschleger, S., Loewith, R., and Hall, M. N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484
2. Sabatini, D. M. (2006)mTORand cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729-734
3. Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35
4. Hay, N., and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945
5. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
6. Hresko, R. C., and Mueckler, M. (2005) mTOR·RICTOR is the Ser-473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406-40416
7. Guertin, D. A., and Sabatini, D. M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9-22
8. Dancey, J. (2010) mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 7, 209-219
9. Shaw, R. J., and Cantley, L. C. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430
10. Xing, M. (2010) Genetic alterations in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Thyroid 20, 697-706
11. Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., and Abraham, R. T. (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60, 3504-3513
12. Edinger, A. L., and Thompson, C. B. (2004) An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 23, 5654-5663
13. Reinke, A., Chen, J. C., Aronova, S., and Powers, T. (2006) Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p. J. Biol. Chem. 281, 31616-31626
14. Urano, J., Sato, T., Matsuo, T., Otsubo, Y., Yamamoto, M., and Tamanoi, F. (2007) Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 104, 3514-3519
15. Ohne, Y., Takahara, T., Hatakeyama, R., Matsuzaki, T., Noda, M., Mizushima, N, and Maeda, T. (2008) Isolation of hyperactive mutants of mammalian target of rapamycin. J. Biol. Chem. 283, 31861-31870
16. Sato, T., Nakashima, A., Guo, L., Coffman, K., and Tamanoi, F. (2010) Single amino acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29, 2746-2752
17. Mavrakis, M., Lippincott-Schwartz, J., Stratakis, C. A., and Bossis, I. (2006) Depletion of type IA regulatory subunit (RIα) of protein kinaseA(PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency. Hum. Mol. Genet. 15, 2962-2971
18. Galoian, K. A., Temple, T. H., and Galoyan, A. (2011) Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin), in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors. Tumour Biol. 32, 745-751
19. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. U.S.A. 95, 1432-1437
20. Murugan, A. K., and Xing, M. (2011) Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71, 4403-4411
21. Murugan, A. K., Dong, J., Xie, J., and Xing, M. (2009)MEK1mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8, 2122-2124
22. Fukui, Y., and Ihara, S. (2010)Amutant of SWAP-70, a phosphatidylinositoltrisphosphate- binding protein, transforms mouse embryo fibroblasts, which is inhibited by sanguinarine. PLoS One 5, e14180
23. Berven, L. A, and Crouch, M. F. (2000) Cellular function of p70S6K: a role in regulating cell motility. Immunol. Cell Biol. 78, 447-451
24. Hou, P., Ji, M., and Xing, M. (2008) Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113, 2440-2447
25. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554
26. Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., and Xing, M. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 93, 3106-3116
27. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068
28. Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., Teague, J., Andrews, J., Barthorpe, S., Beare, D., Buck, G., Campbell, P. J., Forbes, S., Jia, M., Jones, D., Knott, H., Kok, C. Y., Lau, K. W., Leroy, C., Lin, M. L., McBride, D. J., Maddison, M., Maguire, S., McLay, K., Menzies, A., Mironenko, T., Mulderrig, L., Mudie, L., O'Meara, S., Pleasance, E., Rajasingham, A., Shepherd, R., Smith, R., Stebbings, L., Stephens, P., Tang, G., Tarpey, P. S., Turrell, K., Dykema, K. J., Khoo, S. K., Petillo, D., Wondergem, B., Anema, J., Kahnoski, R. J, Teh, B. T., Stratton, M. R., and Futreal, P. A. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histonemodifying genes. Nature 463, 360-363
29. Robbins, C. M., Tembe, W. A., Baker, A., Sinari, S., Moses, T. Y., Beckstrom- Sternberg, S., Beckstrom-Sternberg, J., Barrett, M., Long, J., Chinnaiyan, A., Lowey, J., Suh, E., Pearson, J. V., Craig, D. W., Agus, D. B., Pienta, K. J., and Carpten, J. D. (2011) Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 21, 47-55
30. Kang, S., Bader, A. G., and Vogt, P. K. (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U.S.A. 102, 802-807
31. Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C., Parker, A., O'Meara, S., Avis, T., Barthorpe, S., Brackenbury, L., Buck, G., Clements, J., Cole, J., Dicks, E., Edwards, K., Forbes, S., Gorton, M., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jones, D., Kosmidou, V., Laman, R., Lugg, R., Menzies, A., Perry, J., Petty, R., Raine, K., Shepherd, R., Small, A., Solomon, H., Stephens, Y., Tofts, C., Varian, J., Webb, A., West, S., Widaa, S., Yates, A., Brasseur, F., Cooper, C. S., Flanagan, A. M., Green, A., Knowles, M., Leung, S. Y., Looijenga, L. H., Malkowicz, B., Pierotti, M. A, Teh, B. T., Yuen, S. T., Lakhani, S. R., Easton, D. F., Weber, B. L., Goldstraw, P., Nicholson, A. G., Wooster, R., Stratton, M. R., and Futreal, P. A. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65, 7591-7595
32. Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K. H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., Shaffer, A. L., Romesser, P., Wright, G., Powell, J., Rosenwald, A., Muller-Hermelink, H. K, Ott, G., Gascoyne, R. D., Connors, J. M., Rimsza, L. M., Campo, E., Jaffe, E. S, Delabie, J., Smeland, E. B., Fisher, R. I, Braziel, R. M., Tubbs, R. R., Cook, J. R., Weisenburger, D. D., Chan, W. C., and Staudt, L. M. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119
33. Sturgill, T. W., and Hall, M. N. (2009) Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCα. ACS Chem. Biol. 4, 999-1015
34. Hardt, M., Chantaravisoot, N., and Tamanoi, F. (2011) Activating mutations of TOR (target of rapamycin). Genes Cells 16, 141-151
35. Nawroth, R., Stellwagen, F., Schulz, W. A., Stoehr, R., Hartmann, A., Krause, B. J., Gschwend, J. E., and Retz, M. (2011) S6K1 and 4EBP1 are independent regulated and control cellular growth in bladder cancer. PLoS ONE 6, e27509
36. Magnuson, B., Ekim, B., and Fingar, D. C. (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J. 441, 1-21
37. Vogelstein, B., and Kinzler, K. W. (2004) Cancer genes and the pathways they control. Nat. Med. 10, 789-799
38. Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N. Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C. R., Nohadani, M., Eklund, A. C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P. A., and Swanton, C. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892
39. Volante, M., Rapa, I., Gandhi, M., Bussolati, G., Giachino, D., Papotti, M., and Nikiforov, Y. E. (2009) RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J. Clin. Endocrinol. Metab. 94, 4735-4741
40. Aleskandarany, M. A., Rakha, E. A., Ahmed, M. A., Powe, D. G., Paish, E. C., Macmillan, R. D., Ellis, I. O., and Green, A. R. (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res. Treat. 122, 45-53
41. Ogino, S., Nosho, K., Kirkner, G. J., Shima, K., Irahara, N., Kure, S., Chan, A. T., Engelman, J. A., Kraft, P., Cantley, L. C., Giovannucci, E. L., and Fuchs, C. S. (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 27, 1477-1484
42. Liu, D., Hou, P., Liu, Z., Wu, G., and Xing, M. (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res. 69, 7311-7319
43. Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., Sasazuki, T., Shirasawa, S., Geuna, M., Frattini, M., Baselga, J., Gallicchio, M., Biffo, S., and Bardelli, A. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 120, 2858-2866
44. Liu, R., Liu, D., Trink, E., Bojdani, E., Ning, G., and Xing, M. (2011) The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J. Clin. Endocrinol. Metab. 96, E577-E585
45. Weigelt, B., Warne, P. H., and Downward, J. (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30, 3222-3233